Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $100 Million At-The-Market Offering Facility

Press Release – New York, NY – April 14, 2022 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a late-stage biotechnology company, in a $100 million At-The-Market offering facility (“ATM”).
The shares were registered on RLMD’s Registration Statement on Form S-3 (File No. 333-264189) filed with the Securities and Exchange Commission on April 7, 2022.
Jefferies LLC acted as agent for the ATM.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo and associate Matt Siracusa.
- Sichenzia Ross Ference LLP Represents Spartan Capital Securities, LLC in a $1.25 Million U.S. Private Placement of Alpha Cognition, Inc. - March 16, 2023
- Sichenzia Ross Ference LLP Represents EzFill Holdings, Inc., in $2,096,000 At-The-Market Offering Facility - March 3, 2023
- Sichenzia Ross Ference LLP Represents ShiftPixy, Inc. in $8 Million At-The-Market Offering Facility - March 1, 2023